Amgen announced the submission of a Marketing Authorisation Application to the European Medicines Agency via the centralised procedure for etelcalcetide...
Amgen announced that the FDA has issued a Complete Response Letter for the New Drug Application (NDA) for Parsabiv (etelcalcetide)...
Amgen announced the submission of a New Drug Application (NDA) with the FDA for etelcalcetide (formerly AMG 416) for the...
Amgen has presented the findings from a head-to-head Phase III study comparing intravenous etelcalcetide (AMG 416) with oral cinacalcet (Mimpara)...
Amgen announced that the FDA has approved Parsabiv (etelcalcetide) for the treatment of secondary hyperparathyroidism (HPT) in adult patients with...
Amgen has announced that the European Commission (EC) has granted marketing authorization for Parsabiv (etelcalcetide) for the treatment of secondary...
Amgen has announced the Journal of the American Medical Association (JAMA) publication of findings from three Phase III studies of...